RET and non-small cell lung carcinoma: A total of 22 of 329 patients (7%) with RET fusion-positive NSCLC experienced a treatment-emergent AE reported using the Medical Dictionary for Regulatory Activities preferred term of “hypersensitivity” or “drug hypersensitivity” and attributed to selpercatinib by investigators (Table 2).